0000950103-18-005824.txt : 20180503 0000950103-18-005824.hdr.sgml : 20180503 20180503122738 ACCESSION NUMBER: 0000950103-18-005824 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20180503 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180503 DATE AS OF CHANGE: 20180503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37896 FILM NUMBER: 18802700 BUSINESS ADDRESS: STREET 1: BLOCK 2, MIESIAN PLAZA STREET 2: 50-58 BAGGOT STREET LOWER CITY: DUBLIN 2 STATE: L2 ZIP: D02 HW68 BUSINESS PHONE: 353-1-609-6000 MAIL ADDRESS: STREET 1: BLOCK 2, MIESIAN PLAZA STREET 2: 50-58 BAGGOT STREET LOWER CITY: DUBLIN 2 STATE: L2 ZIP: D02 HW68 FORMER COMPANY: FORMER CONFORMED NAME: Shire Ltd. DATE OF NAME CHANGE: 20080523 FORMER COMPANY: FORMER CONFORMED NAME: Shire plc DATE OF NAME CHANGE: 20051125 FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp90676_8k.htm FORM 8-K

 


  
  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): May 3, 2018
 
SHIRE PLC
(Exact name of registrant as specified in its charter)
 
Jersey, Channel Islands 0-29630 98-0601486
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

Block 2

Miesian Plaza

50-58 Baggot Street Lower

Dublin 2

Republic of Ireland
(Address of principal executive offices)

 

   
Registrant’s telephone number, including area code:     +353 1 609 6000
(Former name or former address, if changed since last report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

 

 

 

Item 8.01. Other Events

 

Shire plc has issued the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits. The following exhibits are filed herewith:

 

99.1       Press Release dated May 3, 2018

 

99.2       Press Release dated May 3, 2018

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

   
99.1   Press Release dated May 3, 2018
     
99.2   Press Release dated May 3, 2018

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Shire plc
   
       
  By:  /s/ W R Mordan
    Name:  Bill Mordan
    Title: Company Secretary

 

 

Date: May 3, 2018

 

 

EX-99.1 2 dp90676_ex9901.htm EXHIBIT 99.1

EXHIBIT 99.1

 

 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

3 May 2018

 

Shire plc (“Shire” or the “Company”)

 

Rule 2.9 Announcement

 

In accordance with Rule 2.9 of the City Code on Takeovers and Mergers, the Company confirms that, as at the close of business on 2 May 2018, being the last business day prior to the date of this announcement, it had 920,959,398 ordinary shares of 5 pence each in issue and admitted to trading on the main market of the London Stock Exchange. Shire holds 7,357,283 ordinary shares in treasury. Accordingly, the total number of voting rights in Shire is 913,602,115. The International Securities Identification Number (“ISIN”) for Shire’s ordinary shares is JE00B2QKY057.

 

Shire has an American Depositary Share (“ADS”) programme for which Citibank, N.A. acts as depositary. One ADS represents three ordinary shares of 5 pence each, with ISIN US2481R1068. The ADSs trade on the NASDAQ Global Select Market.

 

Enquiries:

 

 

Shire plc

 

Christoph Brackmann (Investor Relations) +41 795 432 359
Sun Kim (Investor Relations) +1 617 588 8175
Katie Joyce (Media) +1 781 482 2779

 

EX-99.2 3 dp90676_ex9902.htm EXHIBIT 99.2

 

EXHIBIT 99.2

 

 

 

Press Release SL_rgb_lo_blue_pms3005 release.jpg 
www.shire.com  

 

Director/PDMR Shareholding

 

May 3, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)

 

Notification of transactions by person discharging managerial responsibilities

 

1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”)
a) Name Matt Walker
2. Reason for the notification
a) Position / status Head of Technical Operations - PDMR
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a) Name Shire plc
b) LEI 54930005LQRLI2UXRQ59
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction

Receipt of ADSs following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 (“LTIP”) on May 2, 2016. In accordance with the rules of the LTIP, upon vesting the number of ADSs to be delivered was increased by an amount equivalent to the value of dividends paid by the Company in respect of the RSUs from the award date to the date of vesting.

 

(Details of related disposal of ADSs are referenced in section 5. below.)

c) Price(s) and volume(s) Price(s) Volume(s)
$0 822
d)

Aggregated information

 

- Aggregated volume

- Price

N/A (single transaction)
e) Date of the transaction May 2, 2018
f) Place of the transaction N/A

 

 

 

 

5. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument

Shire plc American Depositary Shares (“ADSs”)

 

Identification code ISIN: US82481R1068
b) Nature of the transaction Automated disposal of ADSs in relation to the vesting of RSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c) Price(s) and volume(s) Price(s) Volume(s)
$159.4427 322
d)

Aggregated information

 

- Aggregated volume

- Price

N/A (single transaction)
e) Date of the transaction May 2, 2018
f) Place of the transaction NASDAQ

 

Oliver Strawbridge

 

Senior Assistant Company Secretary

 

For further information please contact:

 

Investor Relations    
Christoph Brackmann christoph.brackmann@shire.com +41 795 432 359
Robert Coates rcoates@shire.com +44 203 549 0874
Sun Kim sun.kim@shire.com +1 617 588 8175
Media    
Katie Joyce kjoyce@shire.com   +1 781 482 2779

 

NOTES TO EDITORS

 

About Shire

 

Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

 

We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.

 

www.shire.com

 

 

 

 

GRAPHIC 4 image_001.jpg GRAPHIC begin 644 image_001.jpg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end